🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Germany
Clinical trial register · Germany

Studies with a German investigative site

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5051 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:51 UTC
5051
Studies in scope
all four open statuses
2882
Recruiting now
open to new participants
988
Lead sponsors
across recruiting studies
Top sites
Essen 50 Berlin 45 Cologne 29 Dresden 29 Hamburg 26
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca185 Novartis Pharmaceuticals142 Hoffmann-La Roche101 Charite University, Berlin, Germany99 Merck Sharp & Dohme LLC97 Clear sponsor filter
Site location
Essen50 Berlin45 Cologne29 Dresden29 Hamburg26
All 116 locations
Target enrolment
to

Trials in this register

142 of 5051 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Germany
Start
Recruiting
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
NCT05268289Lupus Nephritis
DrugIptacopan
Novartis Pharmaceuticals
Phase 2
240
Munich, Ludwigshafen, Frankfurt am Main, Braunschweig, Cologne, Berlin, Mainz
2022-08-10
Active, closed
Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome
NCT05349214Sjogren Syndrome
DrugIanalumab
Novartis Pharmaceuticals
Phase 3
506
Cologne, Dresden, Berlin, Hanover, Herne
2022-08-04
Active, closed
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
NCT05126277Lupus Nephritis
DrugIanalumab
Novartis Pharmaceuticals
Phase 3
452
Aachen, Bochum
2022-07-14
Active, closed
A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab
NCT05142696Extensive Stage Small Cell Lung Cancer
Drugs[177Lu]Lu-DOTA-TATE·[68Ga]Ga-DOTA-TATE·Atezolizumab
Novartis Pharmaceuticals
Phase 1/2
55
Essen
2022-07-13
Active, closed
A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas
NCT05415072Metastatic Uveal Melanoma
Novartis Pharmaceuticals
Phase 1/2
66
Essen, Heidelberg
2022-07-04
Recruiting
A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis
NCT05344469Relapsing Multiple Sclerosis
Novartis Pharmaceuticals
Observational
800
Albstadt, Hettingen, Mannheim, Nagold, Schwäbisch Hall, Schwetzingen, Bamberg, Dillingen an der Donau
2022-05-10
Recruiting
Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia
NCT04925479Myeloid Leukemia, Philadelphia Positive
DrugABL001
Novartis Pharmaceuticals
Phase 1/2
34
Erlangen, Essen, Hamburg
2021-12-27
Active, closed
Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.
NCT05038735Breast Cancer
DrugsAlpelisib·Fulvestrant
Novartis Pharmaceuticals
Phase 3
210
Cologne, Augsburg, Berlin, Essen, Lübeck
2021-12-17
Active, closed
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)
NCT05156281Relapsing Multiple Sclerosis
DrugsTeriflunomide·Remibrutinib
Novartis Pharmaceuticals
Phase 3
1,007
Freiburg im Breisgau, Essen, Hamburg
2021-12-13
Active, closed
A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors
NCT04857372Mesothelioma
Novartis Pharmaceuticals
Phase 1
137
Essen
2021-10-21
Active, closed
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
NCT04971226Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
DrugsABL001·Bosutinib·Asciminib·Nilotinib
Novartis Pharmaceuticals
Phase 3
405
Mannheim, Frankfurt am Main, Jena, Aachen, Berlin, Lübeck
2021-10-06
Active, closed
Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis
NCT04926818Multiple Sclerosis (MS)
DrugsSiponimod·Fingolimod·Ofatumumab
Novartis Pharmaceuticals
Phase 3
129
Freiburg im Breisgau, Göttingen, Bochum
2021-10-05
Active, closed
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
NCT04557462Primary IgA Nephropathy
DrugIptacopan
Novartis Pharmaceuticals
Phase 3
448
Freiburg im Breisgau, Stuttgart, Aachen, Berlin, Essen, Hanover, Kiel, Magdeburg
2021-09-20
Recruiting
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
NCT04817618C3G
DrugIptacopan
Novartis Pharmaceuticals
Phase 3
98
Cologne, Aachen, Erlangen, Essen, Hamburg, Hanover, Heidelberg, Mainz
2021-07-28
Active, closed
Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria
NCT04747613Paroxysmal Nocturnal Hemoglobinuria
DrugIptacopan
Novartis Pharmaceuticals
Phase 3
208
Dresden, Aachen, Essen, Hamburg, Riesa, Ulm
2021-07-27
Active, closed
177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer
NCT04689828Prostatic Neoplasms
DrugsARDT·68Ga-PSMA-11·Pluvicto
Novartis Pharmaceuticals
Phase 3
469
Essen, München
2021-06-15
Recruiting
Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study
NCT04657822Sickle Cell Disease
DrugCrizanlizumab
Novartis Pharmaceuticals
Phase 4
130
Heidelberg
2021-06-10
Active, closed
An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
NCT04720157Prostatic Neoplasms
DrugsARDT·68Ga-PSMA-11·Pluvicto
Novartis Pharmaceuticals
Phase 3
1,140
Würzburg, Cologne, Essen, München, Münster, Rostock
2021-06-09
Active, closed
Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum
NCT04589650PIK3CA-related Overgrowth Spectrum (PROS)
DrugAlpelisib
Novartis Pharmaceuticals
Phase 2
206
Freiburg im Breisgau, Düsseldorf, Leipzig, Hamburg, Heidelberg
2021-04-19
Active, closed
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
NCT04603495Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
DrugsPelabresib·Ruxolitinib
Novartis Pharmaceuticals
Phase 3
430
Ulm, Augsburg, Halle, Jena, Hamburg
2021-04-09
Active, closed
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
NCT04699188KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal, Cancer of Lung
DrugsTNO155·JDQ443·Tislelizumab
Novartis Pharmaceuticals
Phase 1/2
344
Freiburg im Breisgau, Cologne, Dresden, Essen
2021-02-24
Active, closed
Atrasentan in Patients With IgA Nephropathy
NCT04573478IgA Nephropathy, Immunoglobulin A Nephropathy
DrugsAtrasentan·Zigakibart
Novartis Pharmaceuticals
Phase 3
404
Cloppenburg, Hanover, Hoyerswerda, Jena, Villingen-Schwenningen, Würzburg
2020-12-11
Active, closed
Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma
NCT04417621Melanoma
DrugsNaporafenib·Trametinib·Ribociclib
Novartis Pharmaceuticals
Phase 2
134
Dresden, Essen, Heidelberg, Tübingen
2020-10-30
Active, closed
Pediatric Long-Term Follow-up and Rollover Study
NCT03975829Diffuse Astrocytoma, Anaplastic Astrocytoma, Astrocytoma, Oligodendroglioma, Childhood
DrugsDabrafenib·Trametinib
Novartis Pharmaceuticals
Phase 4
163
Cologne, Augsburg, Berlin, Essen, Hamburg
2019-11-04
Active, closed
Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments
NCT04058756Advanced Solid Tumors
DrugSpartalizumab
Novartis Pharmaceuticals
Phase 1
120
Jena, Essen, Heidelberg, Ulm
2019-10-30
Recruiting
Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN
NCT03955445C3 Glomerulopathy, Immune-complex-membranoproliferative Glomerulonephritis
DrugIptacopan
Novartis Pharmaceuticals
Phase 3
225
Erlangen, Essen, Hamburg, Heidelberg, Mainz
2019-10-03
Active, closed
Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients
NCT03814746Sickle Cell Disease (SCD)
DrugCrizanlizumab
Novartis Pharmaceuticals
Phase 3
254
Stuttgart, Cologne, Berlin, Essen
2019-07-26
Active, closed
Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
NCT03960840Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia
DrugIbrutinib
Novartis Pharmaceuticals
Phase 1/2
217
Frankfurt am Main, Leipzig
2019-06-26
Active, closed
Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.
NCT03891953Carcinoma, Non-Small-Cell Lung, Melanoma, Nasopharyngeal Carcinoma, Microsatellite Stable Colorectal Cancer
DrugSpartalizumab
Novartis Pharmaceuticals
Phase 1
98
Dresden, Essen
2019-05-07
Active, closed
A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML
NCT03591510FLT3-mutated Acute Myeloid Leukemia
DrugsMidostaurin·Mitoxantrone·Idarubicin·Daunorubicin
Novartis Pharmaceuticals
Phase 2
22
Berlin, Essen
2019-03-13
Active, closed
Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa
NCT03827798Hidradenitis Suppurativa
DrugsMAS825·Ianalumab·Remibrutinib
Novartis Pharmaceuticals
Phase 2
248
Bochum, Frankfurt, Hamburg, Schwerin
2019-02-27
Active, closed
Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS
NCT03650114Relapsing Multiple Sclerosis
Drugs13-valent pneumococcal conjugate vaccine·23-valent pneumococcal polysaccharide vaccine·Ofatumumab
Novartis Pharmaceuticals
Phase 3
1,882
Munich, Neuburg A.d. Donau, Unterhaching, Marburg, Cologne, Dresden, Leipzig, Barsinghausen
2018-12-28
Active, closed
A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer
NCT03701334Early Breast Cancer
DrugRibociclib
Novartis Pharmaceuticals
Phase 3
5,101
Ravensburg, Munich, Würzburg, Cottbus, Frankfurt am Main, Georgsmarienhütte, Hanover, Essen
2018-12-07
Active, closed
Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC
NCT03333343EGFR-mutant Non-small Cell Lung Cancer
DrugsNaporafenib·Capmatinib·Gefitinib·Trametinib
Novartis Pharmaceuticals
Phase 1
105
Cologne, Essen
2018-01-29
Recruiting
Dabrafenib and/or Trametinib Rollover Study
NCT03340506Melanoma, Non Small Cell Lung Cancer, Solid Tumor, Rare Cancers
DrugsDabrafenib·Trametinib
Novartis Pharmaceuticals
Phase 4
100
Mannheim, Augsburg, Berlin, Essen, Hamburg, Heidelberg
2018-01-26
Active, closed
Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone
NCT03040973Advanced Solid Tumors Which Are cMET-dependent
DrugsCapmatinib·Gefitinib·Osimertinib
Novartis Pharmaceuticals
Phase 2
29
Cologne, Hanover
2017-07-04
Active, closed
Ribociclib (LEE011) Rollover Study for Continued Access
NCT02934568Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies
DrugRibociclib
Novartis Pharmaceuticals
Phase 2
22
Cologne
2016-12-15
Active, closed
Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study
NCT02584933ALK Positive Malignancies
DrugCeritinib
Novartis Pharmaceuticals
Phase 4
233
Regensburg, Cologne, Essen, Heidelberg, Würzburg
2015-12-11
Recruiting
CAR-T Long Term Follow Up (LTFU) Study
NCT02445222Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program
Novartis Pharmaceuticals
Phase 3
1,400
Munich, Regensburg, Würzburg, Frankfurt am Main, Cologne, Leipzig, Berlin, Hamburg
2015-11-02
Active, closed
A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations
NCT02381886Advanced Malignancies That Harbor IDHR132 Mutations
Novartis Pharmaceuticals
Phase 1
166
Cologne, Jena, Heidelberg
2015-03-06
Active, closed
CINC424A2X01B Rollover Protocol
NCT02386800Primary Myelofibrosis, Polycythemia Vera, Graft Versus Host Disease, Acute Myeloid Leukemia
DrugRuxolitinib
Novartis Pharmaceuticals
Phase 4
279
Dresden, Jena, Aachen, Hamburg, Magdeburg, Mainz, Ulm
2015-03-05
Active, closed
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
NCT01892722Multiple Sclerosis
DrugsRebif·Fingolimod
Novartis Pharmaceuticals
Phase 3
240
Freiburg im Breisgau, Göttingen, Dresden, Bochum, Erlangen
2013-07-26
Rows per page Showing 101–142 of 142
Previous 1 2
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 27 September 2026. https://priyalifescience.com/clinical-trials-germany?page=2

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,051 studies in total at the last sync on 26 Sep 2026, 19:51 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 142 of those studies that match the filters currently applied.

How many clinical trials are recruiting in Germany?

58 of the 142 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:51 UTC sync. A further 0 have not yet opened recruitment, 84 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

This register, in your inbox every Friday

One email a week with how many trials are recruiting in Ireland, new EMA and FDA approvals and medicine shortages, built from the same public registers as this page.

Free. Unsubscribe from any email with one click. See our privacy policy.

→

Browse trials by condition

Relapsing Multiple Sclerosis (5) Chronic Spontaneous Urticaria (5) Lupus Nephritis (4) Carcinoma, Non-Small-Cell Lung (4) Hidradenitis Suppurativa (4) Systemic Lupus Erythematosus (3) Breast Cancer (3) Multiple Sclerosis (3) Melanoma (3) Primary Immune Thrombocytopenia (2) Advanced HR+/HER2- Breast Cancer (2) Advanced CCNE1-amplified Solid Tumors (2) IgA Nephropathy (2) Immunoglobulin A Nephropathy (2) Prostatic Neoplasms (2)
→

Browse trials by site location

Essen (50) Berlin (45) Cologne (29) Dresden (29) Hamburg (26) Freiburg im Breisgau (25) Frankfurt am Main (22) Mainz (21) Munich (21) Jena (21) Leipzig (20) Heidelberg (16) Hanover (15) Würzburg (15) Ulm (14)
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.